Unknown

Dataset Information

0

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.

ABSTRACT:

SUBMITTER: Sivaraj D 

PROVIDER: S-EPMC6068091 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.

Sivaraj Dharshan D   Green Michael M MM   Kang Yubin Y   Long Gwynn D GD   Rizzieri David A DA   Li Zhiguo Z   Garrett Anderson H AH   McIntyre Jackie L JL   Chao Nelson J NJ   Gasparetto Cristina C  

Blood cancer journal 20180731 8

Similar Datasets

Unknown Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
| S-EPMC7685974 | biostudies-literature
Unknown Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
| S-EPMC5570682 | biostudies-literature
Unknown Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma.
| S-EPMC5606008 | biostudies-literature
Unknown Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
| S-EPMC4643003 | biostudies-literature
Unknown Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma.
| S-EPMC9109494 | biostudies-literature
Unknown Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
| S-EPMC11925518 | biostudies-literature
Unknown Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.
| S-EPMC7027539 | biostudies-literature
Unknown Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
| S-EPMC6391672 | biostudies-literature
Unknown Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma.
| S-EPMC6663939 | biostudies-literature
Unknown Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma.
| S-EPMC12908833 | biostudies-literature